FLORHAM PARK, N.J. and NEW YORK, Jan. 8, 2021 — Celularity, Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and GX Acquisition Corp. (Nasdaq: GXGX), a special purpose acquisition company, today announced they have entered into a definitive merger agreement pursuant to which GX Acquisition Corp. will combine with Celularity. Upon the closing of the transaction, which is expected to occur in the second quarter of 2021, GX Acquisition Corp. will be renamed Celularity Inc., and its common stock and warrants are expected to remain listed on Nasdaq under the new ticker symbols “CELU” and “CELUW.” [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
Helixmith Announces the Development of Botanical Therapeutic Product for Respiratory Diseases, TADIOS
-
Encouraging animal model efficacy data has been published in Journal of Ethnopharmacology
-
Clinical trial of 100 patients diagnosed with COVID-19 to begin soon in India
-
TADIOS found to have anti-inflammatory, anti-oxidative activities and therapeutic effects in acute lung injury animal model
January 14, 2021 – Helixmith Co., Ltd. has announced that TADIOS (HX110), a respiratory treatment developed by the company, showed lung damage-suppressing capability in an acute lung injury mouse model. The results have been published in the Journal of Ethnopharmacology. Helixmith plans to conduct a clinical trial in India to assess if TADIOS can be used as a COVID-19 treatment. Helixmith has signed an agreement with a contract research organization (CRO) that has extensive experience and capacities in the conduct of clinical trials in India. The clinical trial will be conducted in accordance with the regulations of the Ministry of AYUSH, India’s traditional medicine regulatory body, and will begin in February with 100 subjects. [Read more…]
Implant Therapeutics To Engineer iPSC-MSC Cells Containing panCELLa’s Technologies
TORONTO, Jan. 8, 2021– panCELLa’s intent to develop therapeutic products in the mesenchymal stem cell (MSC) and pancreatic islet space has recently led to the creation of Implant Therapeutics.
Implant Therapeutics, under the guidance of Dr. Mahendra Rao, is engineering iPSC-MSC cells containing panCELLa’s FailSafe™ and induced Allogeneic Cell Tolerance (iACT Stealth Cell™) technologies. These iPSC MSC cells are hypo-immunogenic and are an ideal choice for bone, cartilage and tendon replacement strategies combining the advantages of allogeneic and autologous cells as well as allowing them to be used as ex-vivo gene therapy vehicles. [Read more…]
The Forgotten Ones. Will Long-Haulers Be the Next Public Health Crisis?
A LIVE ONLINE DISCUSSION ON COVID-19 LONG-HAULERS HOSTED BY ORGANICELL REGENERATIVE MEDICINE, INC.
Miami Beach, Florida, January 12th, 2021 — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) (the “Company” or “Organicell”), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies will host a live online discussion on the topic of COVID-19 long-haulers on Wednesday, January 13th at 7 P.M. EST. [Read more…]
Evotec Achieves Milestone within iPSC-Based Neuroscience Partnership with BMS
Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry.
HAMBURG, GERMANY / January 5, 2021 — Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced that the Company has received a US $6 million payment from Bristol Myers Squibb Company (NYSE: BMY) within the companies’ iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb’s decision to add another drug discovery project to the partnership’s portfolio. [Read more…]
- « Previous Page
- 1
- …
- 88
- 89
- 90
- 91
- 92
- …
- 144
- Next Page »